ARTICLE | Clinical News
ISIS-TTRRx regulatory update
April 28, 2014 7:00 AM UTC
The European Commission granted Orphan Drug designation to ISIS-TTRRx from Isis to treat transthyretin (TTR) amyloidosis. The TTR antisense inhibitor is in Phase II/III testing to treat familial amyl...